Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time

How aggressive is bladder cancer? Understand what percentage of bladder tumors are cancerous and the dangerous, powerful role of tumor grade.

Bladder cancer is a big health issue, ranking as the sixth most common cancer in the U.S. It’s expected to affect over 84,000 people in 2025. Knowing how aggressive it is is key to good care.

What Percentage of Bladder Tumors Are Cancerous:Aggression
What Percentage of Bladder Tumors Are Cancerous:Aggression Action 4

Bladder cancer’s aggressiveness varies a lot. Early stages can often be treated, but advanced cases can spread fast and be deadly. About 25% of cases are muscle-invasive at diagnosis, showing the need for quick and thorough treatment.

At livhospital.com, we want to give a full look at bladder cancer. We cover its aggressiveness and how many bladder tumors are cancerous. Our goal is to offer top-notch healthcare.

Key Takeaways

  • Bladder cancer is the sixth most common cancer in the United States.
  • Over 84,000 new bladder cancer cases are expected in 2025.
  • Approximately 25% of bladder cancer cases are muscle-invasive at diagnosis.
  • Understanding bladder cancer’s aggressiveness is vital for prevention and effective care.
  • Early-stage bladder cancer is often treatable, but advanced cases can be life-threatening.

Bladder Cancer: A Major Health Concern in the United States

Bladder cancer is a big health problem in the United States. It affects many people every year. The National Cancer Institute says it’s one of the top cancers in the U.S. The first sign is often blood in the urine.

The Sixth Most Common Cancer: Incidence and Mortality

Bladder cancer is the sixth most common cancer in the United States. We’ll look at how common it is and how many people die from it. Many things can affect how likely someone is to get bladder cancer, like age, gender, and lifestyle.

Some important facts are:

  • Men are more likely to get bladder cancer than women.
  • Most bladder cancer cases happen in people over 55.
  • Smoking is a big risk factor for bladder cancer.

Risk Factors: Age, Gender, and Lifestyle Influences

Knowing the risk factors is key to preventing and catching bladder cancer early. We’ll talk about how age, gender, and lifestyle affect bladder cancer risk.

What Percentage of Bladder Tumors Are Cancerous:Aggression
What Percentage of Bladder Tumors Are Cancerous:Aggression Action 5

By understanding these risk factors, people can take steps to lower their chance of getting bladder cancer.

What Percentage of Bladder Tumors are Cancerous

We will look into how many bladder tumors are cancerous. Bladder tumors are growths in the bladder. They can be either harmless or harmful.

Distinguishing Between Benign and Malignant Bladder Growths

Not all bladder tumors are cancerous. Some are harmless growths that don’t harm the bladder or spread. But about 25% of bladder cancer cases are muscle-invasive at diagnosis. This changes how they are treated and their outlook.

Tests like cystoscopy and biopsy are key in finding bladder cancer. A doctor uses a cystoscope to look inside the bladder. If they see something suspicious, a biopsy is done to check for cancer.

The 25% Rule: Muscle-Invasive Cases at Diagnosis

About 25% of bladder cancer cases are muscle-invasive at diagnosis. This shows why early detection and accurate diagnosis are so important. Muscle-invasive bladder cancer is more serious and needs stronger treatments like surgery, chemotherapy, or radiation.

Diagnostic Accuracy and Challenges in Detection

Getting the right diagnosis is key to treating bladder cancer. But there are challenges like false negatives or positives. To get better results, using a mix of diagnostic tests is common. This includes imaging tests like CT scans and MRI.

The main challenges are:

  • Telling benign from malignant tumors
  • Finding cancer early
  • Watching for cancer coming back after treatment
What Percentage of Bladder Tumors Are Cancerous:Aggression
What Percentage of Bladder Tumors Are Cancerous:Aggression Action 6

The Spectrum of Bladder Cancer Aggressiveness

It’s important to know how aggressive bladder cancer can be. This helps doctors choose the best treatment for each patient. Every case is different, so a personalized plan is needed.

Non-Muscle Invasive Bladder Cancer: The Less Aggressive Form

Non-muscle invasive bladder cancer (NMIBC) stays in the bladder’s lining. It’s less aggressive and has a better chance of recovery. Treatment options often include removing the tumor and using medicine inside the bladder.

  • Early detection improves outcomes
  • Regular follow-ups are key
  • Intravesical therapy can lower recurrence

Muscle-Invasive Bladder Cancer: When Aggression Increases

Muscle-invasive bladder cancer (MIBC) goes deeper into the bladder muscle. It’s more aggressive and risky. Aggressive treatments like removing the bladder or chemotherapy are often needed.

  1. Radical cystectomy is a big surgery
  2. Chemotherapy can be used before or after surgery
  3. Team care is vital

Metastatic Bladder Cancer: The Most Aggressive Presentation

Metastatic bladder cancer is the most aggressive. It has spread to other parts of the body. Treatment aims to manage symptoms and improve life quality. Options include chemotherapy and immunotherapy.

Understanding bladder cancer’s aggressiveness is critical. Tailoring treatments to each patient can lead to better outcomes and quality of life.

Survival Rates That Tell the Story of Aggressiveness

The fight against bladder cancer is closely tied to survival rates. Early detection is key. Knowing the survival rates helps patients and doctors make better treatment plans.

Early-Stage Bladder Cancer: 72-78% Five-Year Survival

Early-stage bladder cancer has a 72% to 78% five-year survival rate. This shows how vital early detection is. A study onNCBI found that early diagnosis greatly improves chances. Early detection and the right treatment are key to better survival rates.

Stage 2 Bladder Cancer Prognosis: What to Expect

Stage 2 bladder cancer means the cancer has grown through the bladder’s muscle layer. It hasn’t spread to lymph nodes or distant sites yet. The survival rate for Stage 2 varies, but with the right treatment, patients can have a good prognosis. Treatment, like surgery and chemotherapy, greatly affects the outcome.

Stage 3 and Metastatic Disease: When Survival Drops to 9%

Stage 3 and metastatic bladder cancer have a survival rate of about 9%. This shows how aggressive the disease is when it spreads. Survival depends on how far it has spread and the patient’s health. Aggressive treatments are needed to improve survival chances.

Survival rates for bladder cancer show how aggressive the disease is and how well treatments work. By understanding these rates, patients and doctors can better handle bladder cancer care.

Why Bladder Cancer Returns: Understanding Recurrence Patterns

It’s important to know why bladder cancer comes back. This is key to managing it well. Bladder cancer can return even after treatment.

Can Bladder Cancer Return After Bladder Removal?

Yes, bladder cancer can come back after removing the bladder. This is called radical cystectomy. The chance of it coming back depends on the cancer’s stage and grade. It’s vital to keep up with follow-up visits to catch any return early.

How Many Times Can You Have TURBT for Bladder Cancer?

Transurethral resection of bladder tumor (TURBT) can be done many times for bladder cancer that keeps coming back. How often you need TURBT depends on your situation and the cancer type.

Some important things to remember:

  • Recurrence risk factors: Knowing what makes recurrence more likely, like the cancer’s stage and grade.
  • Monitoring protocols: Regular check-ups and tests to find recurrence early.
  • Treatment options: There are treatments for bladder cancer that come back, like TURBT, chemotherapy, and immunotherapy.

Monitoring Protocols After Initial Treatment

After the first treatment, it’s important to keep an eye out for any signs of cancer coming back. This includes cystoscopy, imaging tests, and urine tests.

Treatment Success Rates Based on Cancer Aggressiveness

Treatment success for bladder cancer depends on the cancer’s stage and how aggressive it is. Knowing these success rates helps doctors and patients make better choices.

TURBT and Recovery: What to Expect

Transurethral resection of bladder tumor (TURBT) is a common treatment for non-muscle invasive bladder cancer. Most patients see their tumors completely removed. But recovery times can differ, and some might need to urinate more often.

The success of TURBT depends on the tumor’s size, location, and the surgeon’s skill. Patients usually have a good outlook after TURBT. But they need regular check-ups to watch for any signs of the cancer coming back.

Bladder Cancer Chemotherapy Success Rate

Chemotherapy is used for bladder cancer, alone or with surgery, for more serious cases. The success of chemotherapy depends on the cancer’s stage and how aggressive it is. For non-muscle invasive bladder cancer, chemotherapy can lower the chance of it coming back.

Research shows chemotherapy can work well for bladder cancer patients. But the success rate varies based on the patient and the chemotherapy used.

Immunotherapy and Targeted Treatments: Changing the Landscape

Immunotherapy and targeted treatments are new and promising for bladder cancer. They boost the immune system or target cancer growth. These treatments are showing great promise, mainly for advanced or spread-out bladder cancer.

Studies show immunotherapy and targeted treatments can improve survival and quality of life for bladder cancer patients. As research grows, these treatments will likely become more important in treating bladder cancer.

Living With and Beyond Bladder Cancer

Bladder cancer affects more than just the body. It touches the lives of patients and their loved ones deeply. We must think about the quality of life for those affected.

Quality of Life After Different Treatment Approaches

Treatment for bladder cancer can greatly affect a patient’s life. Surgery, chemotherapy, and immunotherapy have different effects. For example, surgery might change how you use the bathroom, while chemotherapy can cause fatigue and other side effects.

“Personalized care and support are key to a good quality of life,” experts say. They stress the importance of treatment plans that fit each patient’s needs.

Mayo Clinic Bladder Cancer Protocols and Innovations

The Mayo Clinic is known for its new ways to treat bladder cancer. They use the latest research and technology to create personalized treatment plans. These plans aim to fight cancer while keeping the patient’s quality of life in mind.

Mayo Clinic teams work closely with patients. They address each patient’s unique needs and concerns.

Psychological Impact and Support Systems

Bladder cancer can deeply affect a patient’s mental health. It’s important for patients to have strong support systems. This includes counseling, support groups, and family networks.

“Support systems are vital for coping with bladder cancer’s emotional and psychological challenges,”

experts say. They emphasize the need for a complete care approach.

By focusing on quality of life and support, we can help patients overcome bladder cancer. They can face challenges with dignity and strength.

Conclusion: Addressing the Question “Is Bladder Cancer Fatal?”

Bladder cancer can be very serious, but early detection and treatment can help a lot. The type of bladder cancer affects how serious it is. Some cancers are not as aggressive, while others are more dangerous.

Knowing about bladder tumors and their aggressiveness is key to treating them well. Even though aggressive bladder cancer is a big concern, new treatments like immunotherapy offer hope. Whether bladder cancer is fatal depends on when it’s found and how well it’s treated.

It’s vital to be aware of and catch bladder cancer early. With the right care, people can fight off aggressive cancer and live longer. By staying informed and proactive, we can all lower our risk and improve our chances of beating bladder cancer.

FAQ

What percentage of bladder tumors are cancerous?

Most bladder tumors are cancerous, but the exact percentage varies. About 25% of bladder cancer cases are muscle-invasive at diagnosis. This indicates a more aggressive form of the disease.

How aggressive is bladder cancer, and what factors influence its aggressiveness?

Bladder cancer’s aggressiveness varies widely. Factors like the stage at diagnosis, whether it’s muscle-invasive, and the presence of metastasis influence it. Non-muscle invasive bladder cancer is generally less aggressive. Muscle-invasive and metastatic bladder cancer are more aggressive.

Can bladder cancer return after bladder removal, and how is recurrence monitored?

Yes, bladder cancer can return even after bladder removal. Monitoring protocols after initial treatment are key. Regular follow-ups are necessary to detect any recurrence early.

What are the survival rates for bladder cancer, and how do they vary by stage?

Survival rates for bladder cancer vary by stage. For early-stage bladder cancer, the five-year survival rate is around 72-78%. For stage 2 bladder cancer, the prognosis varies. For stage 3 and metastatic disease, survival rates drop to around 9%.

How many times can you have TURBT for bladder cancer, and what are the expectations after bladder polyps surgery?

The number of times TURBT can be performed for bladder cancer varies. It depends on the individual case and the recurrence pattern. After bladder polyps surgery, patients may experience urinary frequency. This typically improves over time.

What are the treatment options for bladder cancer, and how do they impact quality of life?

Treatment options for bladder cancer include TURBT, chemotherapy, immunotherapy, and targeted treatments. The choice of treatment depends on the stage and aggressiveness of the cancer. Each can have a different impact on quality of life.

Is bladder cancer fatal, and what are the chances of survival with appropriate treatment?

Bladder cancer can be fatal if not detected and treated early. With appropriate treatment, survival chances vary significantly. They depend on the stage and aggressiveness of the disease.

What is the success rate of bladder cancer chemotherapy, and how does it compare to other treatments?

The success rate of bladder cancer chemotherapy varies. It depends on the stage and aggressiveness of the cancer. Chemotherapy is often used in combination with other treatments. Its success rate can be significant when used appropriately.

How does Mayo Clinic approach bladder cancer treatment, and what innovations are being explored?

Mayo Clinic is at the forefront of bladder cancer treatment. They offer a range of innovative approaches, including immunotherapy and targeted treatments. Their protocols aim to provide the best possible outcomes for patients.

What support systems are available for patients living with bladder cancer?

Patients living with bladder cancer have access to support systems. These include psychological support to help manage the disease’s impact on quality of life.


References

American Cancer Society. (2025). Key statistics for bladder cancer. Cancer.org.https://www.cancer.org/cancer/types/bladder-cancer/about/key-statistics.html

National Cancer Institute. (2025). Bladder cancer survival rates. U.S. National Institutes of Health.https://www.cancer.gov/types/bladder/survival

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Get a Free Quote

Response within 2 hours during business hours

Clinics/branches
GDPR

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
Trusted Worldwide
30
Years of
Experience
30 Years Badge
Health Türkiye Accreditation

Trusted Worldwide

30 Years of Experience

Patient Reviews
Reviews from 9,651
4,9
Was this content helpful?
Your feedback helps us improve.
What did you like?
Share more details about your experience.
You must give consent to continue.

Thank you!

Your feedback has been submitted successfully. Your input is valuable in helping us improve.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 42 01